摘要
干扰素调节因子(IRF)家族包括参与多种生物学过程调控的转录因子。最初被确定为I型干扰素系统的转录调节, IRFs 在适应性免疫,分化和肿瘤发生的细胞生长中发挥了举足轻重的作用。因此,了解IRF的生物学在癌症的发展和进展中宿主反应有十分重要的意义。许多证据表明,不同的IRFs都参与了慢性粒细胞白血病(CML)发病机制中的作用,一种由骨髓增生性疾病的BCR-ABL蛋白引起的失控。BCR-ABL酪氨酸激酶的活性有利于构成细胞的增殖显示,抑制细胞凋亡,使细胞生存在细胞外基质的粘附不恰当。不同的BCR-ABL酪氨酸激酶抑制剂目前被用于慢性粒细胞白血病的治疗。这些药物能够产生长达八年的慢性粒细胞白血病,其特定的总生存率> 90%,只有少数患者会产生药物停药的分子反应。因此,有一个未符合需要的额外的治疗目标,可能会导致大多数患者被诊断为慢性粒细胞白血病痊愈。越来越多的证据表明在CML发病机制中有IRF4和 IRF8两个作用。此外,IRF1是持续在白血病和脊髓发育不良患者中一个或两个等位基因中被删除的。最后,我们发现IRF5是BCR-ABL激酶活性的靶标,并且可以减少慢性粒细胞白血病细胞的增殖。在这篇文章中,我们提供了IRFs对慢性粒细胞白血病作用的更新。
关键词: IRFs;BCR-ABL;CML;造血;细胞增殖;基因调控。
Current Cancer Drug Targets
Title:Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia
Volume: 16 Issue: 7
Author(s): Livia Manzella, Elena Tirrò, Maria Stella Pennisi, Michele Massimino, Stefania Stella, Chiara Romano, Silvia Rita Vitale and Paolo Vigneri
Affiliation:
关键词: IRFs;BCR-ABL;CML;造血;细胞增殖;基因调控。
摘要: The Interferon Regulatory Factor (IRF) family consists of multiple transcription factors involved in the regulation of a variety of biological processes. Originally identified as transcriptional regulators of the type I interferon system, IRFs play a pivotal role in adaptive immunity, cell growth, differentiation and tumorigenesis. Hence, understanding IRF biology has important implications in the host response to cancer development and progression. Many lines of evidence suggest that different IRFs are involved in the pathogenesis of Chronic Myeloid Leukemia (CML), a myeloproliferative disorder caused by the BCR-ABL oncoprotein. BCR-ABL displays constitutive tyrosine kinase activity that favors cell proliferation, inhibits apoptosis and allows cell survival even in the absence of proper adhesion to the extracellular matrix. Different BCR-ABL tyrosine kinase inhibitors are currently available for CML treatment. These drugs are able to generate eight year CML-specific overall survival rates >90%, only a minority of patients will achieve molecular responses compatible with drug discontinuation. Thus, there is an unmet need for additional therapeutic targets that may lead to the cure of most patients diagnosed with CML. A growing body of evidence has suggested a role for both IRF4 and IRF8 in the pathogenesis of CML. Furthermore, IRF1 is consistently deleted at one or both alleles in patients with leukemia and myelodysplasia. Finally, we have recently demonstrated that IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation. In this article, we provide an update on the current knowledge of the role of the IRFs in CML.
Export Options
About this article
Cite this article as:
Livia Manzella, Elena Tirrò, Maria Stella Pennisi, Michele Massimino, Stefania Stella, Chiara Romano, Silvia Rita Vitale and Paolo Vigneri , Roles of Interferon Regulatory Factors in Chronic Myeloid Leukemia, Current Cancer Drug Targets 2016; 16 (7) . https://dx.doi.org/10.2174/1568009616666160105105857
DOI https://dx.doi.org/10.2174/1568009616666160105105857 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Vaccination Against High Blood Pressure
Current Pharmaceutical Design RNA Base Damage and Repair
Current Pharmaceutical Biotechnology Antiplatelet Therapy in Acute Coronary Syndromes. Evidence Based Medicine
Current Pharmaceutical Design Cytokine Expression Profile as Predictive Surrogate Biomarkers for Clinical Events in the Field of Solid Organ Transplantation
Current Protein & Peptide Science Pharmacological Activity of Cardiovascular Agents from Herbal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Suggested Markers for the Diagnosis of Endometriosis
Current Women`s Health Reviews Synthesis and Biological Activities of Some Novel 2-Amino-(5 or 7-Substituted- 2-Oxoindolin-3-Ylidene) Benzoxazole-5-Carbohydrazide Derivatives
Letters in Drug Design & Discovery Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews Towards a Better Understanding of Cardiac and Vascular Disease in Patients with Chronic Kidney Disease
Current Cardiology Reviews Parthenogenetic Cell Lines: An Unstable Equilibrium Between Pluripotency and Malignant Transformation
Current Pharmaceutical Biotechnology Phospho-Specific Antibodies: A Versatile Tool for Phosphoproteomic Studies
Current Proteomics The Role of P2X Receptors in Bone Biology
Current Medicinal Chemistry Nanoemulsion: The Emerging Contrivance in the Field of Nanotechnology
Nanoscience & Nanotechnology-Asia Role of Lysophosphatidylcholine (LPC) in Atherosclerosis
Current Medicinal Chemistry Role of Genomics-Based Strategies in Overcoming Chemotherapeutic Resistance
Current Pharmaceutical Biotechnology Antioxidant Effect of a Nitrated Cyclic Nucleotide Functioning as an Endogenous Electrophile
Current Topics in Medicinal Chemistry Alpha-1-Antitrypsin Deficiency Liver Disease and New Treatment Opportunities
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Adrenergic Regulation of Macrophage-Mediated Innate/Inflammatory Responses in Obesity and Exercise in this Condition: Role of β2 Adrenergic Receptors
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of β 2-Adrenoceptor Activation in Sepsis-Induced Renal Inflammation
Current Immunology Reviews (Discontinued)